Transgene in Collaboration with Emergent BioSolutions to Receive NIH Funding to Support Development of a Novel Immunotherapy against Tuberculosis

04-11-2013 Business Wire HealthComments (0)


Transgene SA (Paris:TNG) (NYSE-Euronext: TNG) announced today that it has been granted a sub-award from Emergent BioSolutions Inc. (NYSE:EBS) under its existing grant of approximately $5 million from the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH)1. The funding will be used to advance Transgene’s tuberculosis (TB) immunotherapy program. Transgene’s TB program is foc

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top